Workflow
天康生物(002100):生猪业务量增本降,饲料销量保持增长

Investment Rating - The investment rating for the company is "Buy" with a target price based on the last closing price of 7.41 [1][4]. Core Insights - The company has shown growth in its pig farming business while reducing costs, and its feed sales continue to grow [1][4]. - For the first three quarters of 2025, the company achieved revenue of 13.61 billion, a year-on-year increase of 4%, but the net profit attributable to shareholders decreased by 27.2% to 411 million [3][4]. - The company expects further cost optimization in production efficiency and other expenses [3]. Revenue and Profitability - In Q3 2025, the company reported revenue of 4.764 billion, a decline of 6.49% year-on-year, with a net profit of 73.46 million, down 74.58% [3]. - The total number of pigs sold in the first three quarters was 2.2823 million, an increase of 6.46% year-on-year [3]. - The comprehensive cost of pig farming in Q3 was 12.78 yuan/kg, down from 13 yuan/kg in the first half of the year [3]. Feed Business Performance - The feed business achieved sales of 2.12 million tons in the first three quarters, a year-on-year increase of 3.62%, with Q3 sales reaching 776,000 tons, up 11.8% [4]. - Pig feed sales increased by 18% to 462,300 tons, while poultry feed sales grew by 8% to 165,500 tons [4]. Profit Forecast and Investment Recommendations - Due to the anticipated decline in pig prices, the profit forecasts for 2025 and 2026 have been lowered, with expected net profits of 585 million and 979 million respectively [4]. - The earnings per share (EPS) are projected to be 0.43 yuan for 2025 and 0.72 yuan for 2026, with corresponding price-to-earnings (PE) ratios of 17.23x and 10.29x [4].